Recipharm announces its intention to acquire Cobra Biomanufacturing
Recipharm AB announced its intention to acquire Cobra Biomanufacturing plc, a UK-based, cGMP compliant contract manufacturer of biopharmaceuticals. This move will considerably broaden Recipharm’s biologics offering whilst providing access to new markets and technologies including the production of proteins, viruses, DNA and cells for use in pre-clinical through to Phase II clinical trials.
With facilities located in Oxford and Keele (UK), Cobra Biomanufacturing is an established provider of DNA for gene therapy. The company has the capability to utilise the MaxXpress maximum protein expression system, harnessing the power of UCOE technology, to deliver high productivity cell lines and strains and reduced manufacturing costs for its clients. Cobra has also established a significant I.P. portfolio around its own oral vaccine technology, ORT-VAC, based on their patented high plasmid maintenance technology. The ORT-VAC technology has the potential to deliver a wide range of vaccines that would be taken orally.
The acquisition of Cobra Biomanufacturing will form an integral part of Recipharm’s strategic goal to increase its footprint in biologics and offer higher volumes of GMP production together with a wider range of services. The move is set to more than double the size of Recipharm’s biologics business. Long-term, Recipharm plans to provide a full suite of ‘one-stop shop’ biologics capabilities, expanding on its current biomanufacturing services and its ability to fill and finish active pharmaceutical ingredients.
Recipharm intends to both retain Cobra Biomanufacturing’s existing expertise and will actively recruit additional personnel to bolster its newly combined biologics business.
Commenting on the news, Thomas Eldered, CEO and managing director of Recipharm, said, “Our intended acquisition of Cobra Biomanufactuing is yet another example of our stated goal to develop world-class development and manufacturing solutions for the biopharmaceutical industry. This operation will run alongside our existing biologics facility in Sweden and complements very well our established capabilities in small molecules. This I believe creates a very strong offering, enabling us to further develop our customer base amongst both emerging biotechnology and large pharmaceutical companies.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
